About Flucelvax®

FLUCELVAX® (Influenza Vaccine) was the first U.S. FDA approved flu vaccine to utilize cell culture technology. It does not contain antibiotics or preservatives. FLUCELVAX® is available to order for the 2015-16 influenza season.1,2

This season, consider a cell-based flu vaccine produced using modern biotechnology. It is not produced in chicken eggs and contains no antibiotics or preservatives.1,2

Cell-Culture Technology

Benefits of Cell-Culture Technology

The FLUCELVAX® production facility, based in Holly Springs, North Carolina, is the first of its kind in the United States.4 FLUCELVAX® is made in the US.

FLUCELVAX® is manufactured differently, but it contains the same seasonal flu strains as a conventional trivalent flu vaccine.1

Presentation, Storage and Handling

FLUCELVAX® is supplied in a carton containing ten 0.5 mL single-dose syringes without needles:

The tip caps of the pre-filled syringes may contain natural rubber latex. The syringe and syringe plunger stopper are manufactured without natural rubber latex.

Store this product refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not use after the expiration date.

Important Safety Information

Contraindication

Warnings & Precautions

Most Common Adverse Reactions

Please see accompanying US Full Prescribing Information for FLUCELVAX®.


References:

  1. FLUCELVAX® (package insert). Cambridge, MA.
  2. FDA approves first seasonal influenza vaccine manufactured using cell culture technology (news release). Silver Spring, MD: U.S. Food and Drug Administration; November 20, 2012.
  3. Centers for Disease Control and Prevention. Cell-based flu vaccines. www.cdc.gov/flu/protect/vaccine/cell-based.htm. Accessed June 18, 2014.
  4. Seqirus Holly Springs cell culture influenza vaccine manufacturing facility first to be declared pandemic ready by US government [news release]. Cambridge, MA: Seqirus.; December 12, 2011
  5. Gregersen JP, Schmitt HJ, Trusheim H, Broker M. Safety of MDCK cell culture-based influenza vaccines. Future Microbiol 2011;6(2):143–152.